Nicotinamide riboside reliably raises the blood pool of a cellular energy coenzyme. Walking in peripheral artery disease and Parkinson movement symptoms are the main clinical hints, still limited. Blood pressure, metabolism, muscle mass, and thinking scores lack consistent human gains. Safety over weeks to a few months is generally favorable, with mild stomach symptoms. Extending healthy human life remains unproven. (Full Review)

Protocol

ChromaDex / Seals–Martens clinical band

500 mg twice daily (1,000 mg/day)

Niagen nicotinamide riboside chloride; split doses used at ≥1,000 mg/day (2–3 hour nucleoside half-life)

Consumer Niagen label

300 mg once daily

Dose-dependent NAD+ at 100, 300, and 1,000 mg

Time of day

Morning or morning-plus-evening

NAD+ follows a circadian rhythm; late dosing is sometimes avoided when sleep is sensitive

Time to effect

Walking Distance in Peripheral Artery Disease

6 months

6-minute walk versus placebo

Motor Scores in Parkinson Disease

4 weeks

1,000–3,000 mg/day in small trials

Systolic Blood Pressure

6 weeks

Crossover trend; not confirmed with exercise

Benefits

Medium: Walking Distance in Peripheral Artery Disease; Motor Scores in Parkinson Disease

Low: Systolic Blood Pressure

Speculative: Circulating Inflammatory Cytokines; Airway Inflammation in COPD; Human Lifespan or Healthspan Extension; Alzheimer-Related Neuronal Biomarkers; Skeletal Muscle Rejuvenation in Healthy Aging

Contraindications

Active neoplastic malignancy (other than treated non-melanoma skin cancer), including disease within ~2 years

Pregnancy and lactation

Children, outside a supervised deficiency or rare-disease protocol

Known hypersensitivity to nicotinamide riboside or capsule excipients

Key Interactions

Other NAD precursors (nicotinamide, nicotinic acid, nicotinamide mononucleotide)

Nicotinic acid (niacin) flush products

Pterostilbene / resveratrol combinations (Elysium Basis-type products)

Methyl donors (trimethylglycine, folate, methylcobalamin)

Levodopa (and other Parkinson medications)

Cytotoxic chemotherapy (cisplatin, paclitaxel, doxorubicin)

OTC (over-the-counter) high-dose vitamin B3 multi-ingredient NAD-precursor products

Risk & Side Effects

High: Mild Gastrointestinal Symptoms

Medium: LDL Increase with Nicotinamide Riboside plus Pterostilbene

Low: Homocysteine Increase at High Dose; Flushing-Like Warmth and Headache

Speculative: Tumor Promotion or Metastasis; Atherosclerotic Plaque Promotion in Mice

Monitoring

Marker	Target	Why
Whole-blood NAD+	No established functional target; track change from personal baseline	Confirms target engagement
Homocysteine	<8 µmol/L	Methylation drain from nicotinamide clearance
hs-CRP	<1.0 mg/L	Systemic inflammation
AST / ALT	<30 U/L	Hepatic tolerance
Systolic / diastolic blood pressure	<120/80 mmHg	Vascular response
eGFR	>90 mL/min/1.73 m² when attainable; otherwise track slope	Renal handling of NAD catabolites
LDL cholesterol	Functional often <70–100 mg/dL depending on risk	Combination-product lipid signal

Cadence: Baseline metabolic panel, blood counts, lipids, seated blood pressure, and whole-blood NAD+ (homocysteine and B-vitamin status at high dose); NAD+ at 4 weeks, then every 3–6 months with homocysteine, liver enzymes, and blood pressure

Qualitative Assessment

Walking capacity or claudication (leg pain on walking) distance in peripheral artery disease
Daytime energy and recovery, interpreted cautiously because of placebo effects
Motor-symptom stability in Parkinson disease, with medication timing held constant
Sleep continuity if dosing is moved later in the day
Gastrointestinal comfort during the first 2 weeks

Nicotinamide Riboside for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment